Top analyst drops jaw-dropping price target on Eli Lilly stock
PositiveFinancial Markets

- Bernstein has raised its price target for Eli Lilly's stock to $1,300 from $1,100, marking an 18% increase and suggesting a potential upside of 21% to 22% based on current prices. This adjustment reflects ongoing confidence in the company's growth trajectory, particularly in the weight-loss drug market.
- The increase in price target is significant as it underscores the strong market performance of Eli Lilly, which has recently achieved a market value of $1 trillion, driven by robust demand for its GLP-1 medications.
- This development highlights a broader trend in the pharmaceutical industry, where companies like Eli Lilly are capitalizing on the rising popularity of weight-loss drugs, while also exploring innovative partnerships with technology firms to enhance drug discovery and efficiency.
— via World Pulse Now AI Editorial System







